Automation in Pharmacovigilance | Best Clinical Research Training Institute | Clinosol Research

 Automation in Pharmacovigilance

Introduction      

Per WHO definition, Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine/vaccine related problem. All medicines and vaccines undergo rigorous testing for safety and efficacy through clinical trials before they are authorized for use.

It is a process of data acquisition (entry), data analysis and giving benefit risk communication. Here we will list out activities that are targets for automation in pharmacovigilance.

In Data Acquisition (entry)

Adverse event and serious adverse event collected and reported in safety database system.

It is mostly transactional (exchange of data)

In Data Analysis

Internal data and external data surveillance occur by medical assessment and medical adjudication.

It is mostly analytical and cognitive (intellectual)

In Benefits Communication

Risk management plan worked as aggregate reporting on the basis of health hazard evaluation and corporate safety review.

Risk management review evaluation is analytical and cognitive.

Aggregate reporting is mostly transactional.

Aggregate reporting is also done by external and internal data surveillance

Medical adjudication studies 7-15 days reporting also form aggregate reporting.

Pharmacovigilance Automation Path

In starting period manual operations occur in pharmacovigilance after the Facilitation of database with workflow lead to automation.

Automation is done by robotic process automation by the enhancement of natural language process and natural language generation.

Nowadays intelligent automation taking the part lead to expansion of pharmacovigilance transaction focused with automation and intellectual theory/practices.

 

Software Automation Prioritization

Comprehensive review of all process in form of number 1-5

Constructing a process to distinct out the cases creating the list of cases by using automation.

Evaluation of the cases based on relevant criteria such as time, adverse event, seriousness, number of population and complete scoring matrix.

Use the scoring 1-5 prioritize the category of cases specific prioritization is to identify best relevant cases.

 


 https://www.clinosol.com/post/automation-in-pharmacovigilance

Comments

Post a Comment

Popular posts from this blog

Soft Robotic Heart Sleeve | Best Clinical Research Training Institute | Clinosol Research

Image
Globally, 41 million people suffer from Heart Failure. Mechanical pumps known as Ventricular Assist Devices (VADs) that pump blood from the ventricles to the aorta and heart transplant are two of the current treatment options; while VADs are improving, patients are still at high risk for blood clots and stroke (brain attack). Harvard researchers drew inspiration from the heart to build a completely new gadget that does not come into touch with blood. Soft pneumatic actuators put around the heart replicate the outer muscle layers of the human heart in the thin silicon sleeve. In a comparable motion to the beating heart, the actuators twist and compress the sleeve. Working of Robotic Heart Sleeve: This device is constructed of silicone, which contracts when exposed to air and expands when exposed to vacuum. It is made to fit over the heart like a sleeve. The device swells and shrinks both circumferentially and helically, similar to the outermost layers of the human heart, which a...
Read more

Safety Aggregate Reporting | Best Clinical Research Training Institute | Clinosol Research

Image
As the name suggests it is an aggregate (collection) of safety data of a particular drug, compiled and submitted periodically to the regulatory agencies to evaluate the risk- benefit balance of drug use. Compared with single case studies, aggregate reporting is stronger evidence concerning drug safety. Adverse drug reactions are one of the leading causes of morbidity and mortality worldwide. Safety aggregate reporting paves way to mitigate the risk of ADR caused by drugs, medical devices or biologicals. It focuses on encapsulating the safety data during both pre and post marketing phase. More importantly during the Post marketing phase, the incidence of time-related side effects can be keenly monitored. In early 1990s the Council for the Organization of Medical Sciences established a safety aggregate reporting techniques as follows: PSUR - Periodic Safety Update Report DSUR - Development Safety Update Report, that has been accepted and implemented widely in many countries under differ...
Read more